Molecular PsychiatryNeurosciencePeer-reviewed journal article
Integrative transcriptomics and electrophysiological profiling of hiPSC-derived neurons identifies novel druggable pathways in Koolen-de Vries Syndrome
Anouk H. A. VerboveniD, Sofía PuvogeliD, Brooke L. LatouriD, Nikki KolstersiD, Elly LewerissaiD, Rachel MijdamiD, Emma DykeiD, Denise Joanne DuineveldiD, Martijn ZoodsmaiD, Willemijn J. J. ClaasseniD, Astrid R. Oudakker, C. Schoenmaker, David A. KooleniD, Bert B A De VriesiD, P. 't HoeniD, K. Linda, Nael Nadif KasriiD
Abstract
Koolen-de Vries Syndrome (KdVS) is a neurodevelopmental disorder (NDD) with no treatment options due to a lack of understanding of its underlying pathophysiology. To investigate neuronal activity in KdVS, human induced pluripotent stem cell (hiPSC)-derived neurons from KdVS and control subjects were cultured on microelectrode arrays (MEAs). Our study identified reduced network burst rates, indicating disorganized network activity in KdVS neurons. To bridge molecular and functional aspects of the syndrome, we developed an experimental framework, MEA-seq, that integrates network activity measurements with high-throughput transcriptome profiling. This approach identified a negative correlation between the expression of the NDD-associated gene CLCN4 and the network burst rate. Consequently, knockdown of CLCN4 in KdVS neurons restored the activity to control level, confirming a causal relationship between increased CLCN4 expression and reduced network burst rate. Additionally, we identified a positive correlation between mitochondrial gene expression and the network burst rate, and identified impaired mitochondrial function in KdVS hiPSC-derived neurons. The transcriptomic signature of KdVS neurons was then used for computational screening against drug perturbation signatures of the LINCS Consortium database, predicting other drug targets and compounds capable of reversing the expression of affected genes in KdVS neurons. We selected 10 compounds for experimental validation, identifying the antioxidant phloretin and the Rho-kinase inhibitor fasudil as potential candidates for restoring the network activity dysfunction in KdVS. We conclude that the integrative molecular and electrophysiological of hiPSC-derived neurons with MEA-seq has excellent potential for identifying novel drugs and druggable pathways for KdVS and other NDDs.
- organism: human
- assay: bulk RNA-seq
- assay: electronic health records
- research focus: drug response / drug discovery
- research focus: differential expression
- research focus: benchmarking
- approach: experimental assay
- approach: statistical model
- Citations
- 3
- FWCI
- 3.96
- Field percentile
- top 12%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Increased HCN1 activity in human excitatory neurons drives excessive network bursting in Dravet syndrome
Federica Riccio, Guilherme Neves, … Juan Burrone·bioRxiv·Oct 3, 2025
- Potentiating NaV1.1 in Dravet syndrome patient iPSC-derived GABAergic neurons increases neuronal firing frequency and decreases network synchrony
Matt R. Kelley, Laura B. Chipman, … Allison P. Berg·bioRxiv·Sep 28, 2023
- Neuronal network dysfunction in a human model for Kleefstra syndrome mediated by enhanced NMDAR signaling
Monica Frega, Katrin Linda, … Nael Nadif Kasri·Nature CommunicationsPeer-reviewed·Oct 30, 2019
- Mistrafficking of KCC2 promotes hyperexcitability in hippocampal circuitry in a murine model of Christianson Syndrome
Jamie Mustian, Haoyi Qiu, … Rebecca Anne McKinney·bioRxiv·Sep 12, 2026
- Modeling and targeting haploinsufficiency in SHINE syndrome
Dania Abdellatif, Mustafa Obeid, Rami I. Aqeilan·bioRxiv·Aug 17, 2026
- Excitatory Cortical Neurons from CDKL5 Deficiency Disorder Patient-Derived Organoids Show Early Hyperexcitability Not Identified in Neurogenin2 Induced Neurons
Madison R. Glass, Dosh Whye, … Mustafa Şahin·Neurobiology of DiseasePeer-reviewed·Sep 8, 2025